Skip to main content

Advertisement

Table 2 Variables at diagnosis of AML patients with t(8;21) who achieved complete remission and received chemotherapy only and allo-HSCT

From: Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Variable All Chemotherapy only Allo-HSCT P value
Total 88 43 45
Age (years) 36 (14–60) 42 (14–60) 36 (14–54) 0.36
Malesa 47 (53%) 19 (44%) 28 (62%) 0.13
WBC (×109/L) 8.3 (1.3–112) 8.1 (1.3–112) 8.6 (1.2–83) 0.41
Blast cells percentage in the bone marrow (%) 46% (18%–87%) 46% (23%–87%) 48% (18%–83%) 0.82
Platelet count (×109/L) 29 (4–187) 30 (5–187) 28 (4–106) 0.38
Other cytogenetic abnormality than t(8;21)a 54 (64%) 24 (59%) 30 (70%) 0.36
RUNX1-RUNX1T1 transcript level 466% (97%–2545%) 532% (186%–2545%) 422% (97%–933%) 0.31
C-KIT mutationa 30 (34%) 15 (35%) 15 (33%) 1.00
  1. RUNX1-RUNX1T1 Runt-related transcription factor 1-RUNX1 translocation partner 1, C-KIT cellular homolog of the viral oncogene v-KIT receptor tyrosine kinase
  2. aThese values are presented as number of patients followed by percentage in parentheses; other values are presented as median followed by a range in parentheses